Business Description
Zevra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4884451075
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.83 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 1.83 | |||||
Debt-to-EBITDA | -1.03 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3.01 | |||||
Beneish M-Score | 36.43 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -38.5 | |||||
3-Year EBITDA Growth Rate | 3.4 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | -24.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 85.79 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.18 | |||||
9-Day RSI | 62.88 | |||||
14-Day RSI | 60.91 | |||||
6-1 Month Momentum % | 23.66 | |||||
12-1 Month Momentum % | 44.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2 | |||||
Quick Ratio | 2 | |||||
Cash Ratio | 1.62 | |||||
Days Sales Outstanding | 167.08 | |||||
Days Payable | 703.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -109.2 | |||||
Shareholder Yield % | -8.54 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.44 | |||||
Operating Margin % | -309.83 | |||||
Net Margin % | -274.1 | |||||
FCF Margin % | -234.74 | |||||
ROE % | -117.77 | |||||
ROA % | -46.14 | |||||
ROIC % | -99.66 | |||||
3-Year ROIIC % | -35.31 | |||||
ROC (Joel Greenblatt) % | -3985.57 | |||||
ROCE % | -57.2 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.22 | |||||
PB Ratio | 10.42 | |||||
EV-to-EBIT | -6.85 | |||||
EV-to-Forward-EBIT | -2.97 | |||||
EV-to-EBITDA | -7.33 | |||||
EV-to-Forward-EBITDA | -25.9 | |||||
EV-to-Revenue | 17.6 | |||||
EV-to-Forward-Revenue | 4.61 | |||||
EV-to-FCF | -7.5 | |||||
Earnings Yield (Greenblatt) % | -14.6 | |||||
FCF Yield % | -13.34 |